Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.01 0.25 (2.13%) Market Cap: 527.03 Mil Enterprise Value: 452.46 Mil PE Ratio: 0 PB Ratio: 5.31 GF Score: 56/100

Y-mAbs Therapeutics, Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 12:30AM GMT
Release Date Price: $32.62 (+9.13%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. We'll go ahead and get started. So welcome, everybody, to the Wednesday afternoon session of the 2020 JPMorgan Health Care Conference. My name's Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.

Our next presenting company is Y-mAbs Therapeutics, and presenting on behalf of the company, we have CEO, Claus Møller. Claus?

Claus Juan MÃ;ller San Pedro
Y-mAbs Therapeutics, Inc. - CEO & Director

¸ -

Thank you very much, Anupam, and thank you, everybody, for coming and listening to Y-mAbs' presentation. Let's jump right into it.

Our mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing key unmet medical needs. We have a lot of passion behind this company. Our Chairman, Thomas Gad, had the unfortunate experience to have a daughter that went through the treatment with both our lead compound. Fortunately, she

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot